Literature DB >> 29340281

Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.

Vishal Sehgal1, Richard Childress1.   

Abstract

Immune check point inhibitors have revolutionized the treatment of metastatic malignancies. They are a promising area in oncology and more drugs are likely to be available in the coming years. Along with the promise of better response oncologically, there is an increased incidence of endocrinopathies related to autoimmunity. This case report illustrates the dramatic development of hypothyroidism in a patient with underlying subclinical hyperthyroidism. It also suggests the potential pretreatment predictors of endocrinopathies related to these immune check point inhibitors.

Entities:  

Keywords:  endocrinopathies; immune check point inhibitors; metastatic malignancy

Year:  2017        PMID: 29340281      PMCID: PMC5767714          DOI: 10.1515/jtim-2017-0039

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN: 2224-4018


  44 in total

Review 1.  [Immunotherapy in lung cancer: checkpoint inhibitors].

Authors:  Thomas Wehler; Beatrice Wehler; Ingo Stehle
Journal:  Dtsch Med Wochenschr       Date:  2015-12-01       Impact factor: 0.628

Review 2.  Recent treatment advances in Hodgkin lymphoma: a concise review.

Authors:  S Arulogun; M Hertzberg; M K Gandhi
Journal:  Intern Med J       Date:  2016-12       Impact factor: 2.048

Review 3.  Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

Authors:  Thomas K Eigentler; Jessica C Hassel; Carola Berking; Jens Aberle; Oliver Bachmann; Viktor Grünwald; Katharina C Kähler; Carmen Loquai; Niels Reinmuth; Martin Steins; Lisa Zimmer; Anna Sendl; Ralf Gutzmer
Journal:  Cancer Treat Rev       Date:  2016-02-18       Impact factor: 12.111

Review 4.  [Immune checkpoint‑targeted cancer immunotherapies].

Authors:  Julian Swatler; Ewa Kozłowska
Journal:  Postepy Hig Med Dosw (Online)       Date:  2016-01-26       Impact factor: 0.270

5.  Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.

Authors:  Shruti Agrawal; Ian Waxman; Alexandre Lambert; Amit Roy; Raymond Darbenzio
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-10       Impact factor: 3.333

6.  Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab.

Authors:  Tomohiko Narita; Naoki Oiso; Yasunori Taketomo; Kazunori Okahashi; Kohei Yamauchi; Masako Sato; Shusuke Uchida; Hiromasa Matsuda; Akira Kawada
Journal:  J Dermatol       Date:  2015-07-22       Impact factor: 4.005

Review 7.  Side-effects of checkpoint inhibitor-based combination therapy.

Authors:  Hampig R Kourie; Jean A Klastersky
Journal:  Curr Opin Oncol       Date:  2016-07       Impact factor: 3.645

8.  Nivolumab Doubles Survival for Patients with HNSCC.

Authors: 
Journal:  Cancer Discov       Date:  2016-05-23       Impact factor: 39.397

9.  The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials.

Authors:  Conghui Jin; Xunlei Zhang; Kuiling Zhao; Jun Xu; Min Zhao; Xiaohong Xu
Journal:  Onco Targets Ther       Date:  2016-03-16       Impact factor: 4.147

10.  Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Authors:  S Bowyer; P Prithviraj; P Lorigan; J Larkin; G McArthur; V Atkinson; M Millward; M Khou; S Diem; S Ramanujam; B Kong; E Liniker; A Guminski; P Parente; M C Andrews; S Parakh; J Cebon; G V Long; M S Carlino; O Klein
Journal:  Br J Cancer       Date:  2016-04-28       Impact factor: 7.640

View more
  1 in total

1.  Small cell lung cancer starting with diabetes mellitus: Two case reports and literature review.

Authors:  Tong Zhou; Yao Wang; Xue Zhao; Yang Liu; Ying-Xuan Wang; Xiao-Kun Gang; Gui-Xia Wang
Journal:  World J Clin Cases       Date:  2019-05-26       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.